182 related articles for article (PubMed ID: 33927959)
1. Metabolically Supported Chemotherapy for Managing End-Stage Breast Cancer: A Complete and Durable Response.
İyikesici MS; Slocum AK; Winters N; Kalamian M; Seyfried TN
Cureus; 2021 Apr; 13(4):e14686. PubMed ID: 33927959
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Metabolically Supported Chemotherapy Combined with Ketogenic Diet, Hyperthermia, and Hyperbaric Oxygen Therapy for Stage IV Triple-Negative Breast Cancer.
İyikesici MS; Slocum AK; Slocum A; Berkarda FB; Kalamian M; Seyfried TN
Cureus; 2017 Jul; 9(7):e1445. PubMed ID: 28924531
[TBL] [Abstract][Full Text] [Related]
3. Current and Emerging Therapies for HER2-Positive Women With Metastatic Breast Cancer.
Porter K; Rosenzweig MQ
J Adv Pract Oncol; 2017 Mar; 8(2):164-168. PubMed ID: 29900024
[No Abstract] [Full Text] [Related]
4. Feasibility study of metabolically supported chemotherapy with weekly carboplatin/paclitaxel combined with ketogenic diet, hyperthermia and hyperbaric oxygen therapy in metastatic non-small cell lung cancer.
Iyikesici MS
Int J Hyperthermia; 2019; 36(1):446-455. PubMed ID: 30931666
[TBL] [Abstract][Full Text] [Related]
5. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
6. Survival outcomes of metabolically supported chemotherapy combined with ketogenic diet, hyperthermia, and hyperbaric oxygen therapy in advanced gastric cancer.
Iyikesici MS
Niger J Clin Pract; 2020 May; 23(5):734-740. PubMed ID: 32367884
[TBL] [Abstract][Full Text] [Related]
7. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
8.
Groheux D; Martineau A; Teixeira L; Espié M; de Cremoux P; Bertheau P; Merlet P; Lemarignier C
Breast Cancer Res; 2017 Jan; 19(1):3. PubMed ID: 28057031
[TBL] [Abstract][Full Text] [Related]
9. Maximizing the Clinical Benefit of Anthracyclines in Addition to Taxanes in the Adjuvant Treatment of Early Breast Cancer.
Curigliano G; Criscitiello C
J Clin Oncol; 2017 Aug; 35(23):2600-2603. PubMed ID: 28661760
[TBL] [Abstract][Full Text] [Related]
10. Paraneoplastic Encephalopathy in a Patient With Metastatic Lung Cancer: A Case Study.
Rowley SM
J Adv Pract Oncol; 2018 Mar; 9(2):216-221. PubMed ID: 30588355
[No Abstract] [Full Text] [Related]
11. Carcinoma En Cuirasse: A Rare but Striking Cutaneous Manifestation of Metastatic Breast Cancer.
Godbole M; Wani K; Zia S; Dabak V
Cureus; 2023 Jun; 15(6):e39838. PubMed ID: 37397657
[TBL] [Abstract][Full Text] [Related]
12. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
13. Breast Reconstruction With Postmastectomy Radiation: Choices and Tradeoffs.
Poppe MM; Agarwal JP
J Clin Oncol; 2017 Aug; 35(22):2467-2470. PubMed ID: 28481705
[TBL] [Abstract][Full Text] [Related]
14. Retrospective analysis of neoadjuvant chemotherapy for breast cancer in Turkish patients.
Duman BB; Afşar ÇU; Günaldi M; Sahin B; Kara IO; Erkisi M; Erçolak V
Asian Pac J Cancer Prev; 2012; 13(8):4119-23. PubMed ID: 23098527
[TBL] [Abstract][Full Text] [Related]
15. Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial.
Park YH; Kim TY; Kim GM; Kang SY; Park IH; Kim JH; Lee KE; Ahn HK; Lee MH; Kim HJ; Kim HJ; Lee JI; Koh SJ; Kim JY; Lee KH; Sohn J; Kim SB; Ahn JS; Im YH; Jung KH; Im SA;
Lancet Oncol; 2019 Dec; 20(12):1750-1759. PubMed ID: 31668850
[TBL] [Abstract][Full Text] [Related]
16. Development of an invasive ductal carcinoma in a contralateral composite nipple graft after an autologous breast reconstruction: a case report.
Kimura M; Narui K; Shima H; Ikejima S; Muto M; Satake T; Tanabe M; Inayama Y; Adachi S; Yamada A; Shimada K; Sugae S; Ichikawa Y; Ishikawa T; Endo I
Surg Case Rep; 2020 Aug; 6(1):203. PubMed ID: 32770432
[TBL] [Abstract][Full Text] [Related]
17. Synchronous bilateral breast cancer: A case report of heterogeneous estrogen receptor status.
Dhadlie S; Whitfield J; Hendahewa R
Int J Surg Case Rep; 2018; 53():102-106. PubMed ID: 30391732
[TBL] [Abstract][Full Text] [Related]
18. [Conversion Therapy for HER2-Positive Metastatic Breast Cancer with Intrathoracic Lymph Node Metastasis].
Kono H; Maeda H; Yao S; Takahashi M; Yokoi S; Goi T; Imamura Y
Gan To Kagaku Ryoho; 2020 Jun; 47(6):977-980. PubMed ID: 32541178
[TBL] [Abstract][Full Text] [Related]
19. Complete Metabolic Response on Interim
Chen S; Ibrahim NK; Yan Y; Wong ST; Wang H; Wong FC
Oncologist; 2017 May; 22(5):526-534. PubMed ID: 28377466
[TBL] [Abstract][Full Text] [Related]
20. Is It Contralateral Axillary Metastasis or Occult Breast Cancer?: A Confusing Case Report.
Son YG; Kim WW; Kim KH; Kim JS
Case Rep Oncol; 2015; 8(3):498-502. PubMed ID: 26668571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
